85 related articles for article (PubMed ID: 16407468)
1. A nonpeptide antagonist reveals a highly glycosylated state of the rabbit kinin B1 receptor.
Fortin JP; Dziadulewicz EK; Gera L; Marceau F
Mol Pharmacol; 2006 Apr; 69(4):1146-57. PubMed ID: 16407468
[TBL] [Abstract][Full Text] [Related]
2. A novel nonpeptide antagonist of the kinin B1 receptor: effects at the rabbit receptor.
Morissette G; Fortin JP; Otis S; Bouthillier J; Marceau F
J Pharmacol Exp Ther; 2004 Dec; 311(3):1121-30. PubMed ID: 15277582
[TBL] [Abstract][Full Text] [Related]
3. Ligand-mediated regulation of kinin receptors in the rabbit.
Marceau F; Adam A; Houle S; Bouthillier J; Bachvarova M; Bachvarov DR
Biol Chem; 2001 Jan; 382(1):131-3. PubMed ID: 11258663
[TBL] [Abstract][Full Text] [Related]
4. Fluorescent ligands of the bradykinin B1 receptors: pharmacologic characterization and application to the study of agonist-induced receptor translocation and cell surface receptor expression.
Bawolak MT; Gera L; Morissette G; Bouthillier J; Stewart JM; Gobeil LA; Lodge R; Adam A; Marceau F
J Pharmacol Exp Ther; 2009 Apr; 329(1):159-68. PubMed ID: 19136639
[TBL] [Abstract][Full Text] [Related]
5. Ligands regulate cell surface level of the human kappa opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists.
Chen Y; Chen C; Wang Y; Liu-Chen LY
J Pharmacol Exp Ther; 2006 Nov; 319(2):765-75. PubMed ID: 16882876
[TBL] [Abstract][Full Text] [Related]
6. Kinin B1 receptor homo-oligomerization is required for receptor trafficking to the cell surface.
Sandén C; Leeb-Lundberg LM
Int Immunopharmacol; 2013 Jan; 15(1):121-8. PubMed ID: 23201435
[TBL] [Abstract][Full Text] [Related]
7. Novel kinin B1 receptor agonists with improved pharmacological profiles.
Côté J; Savard M; Bovenzi V; Bélanger S; Morin J; Neugebauer W; Larouche A; Dubuc C; Gobeil F
Peptides; 2009 Apr; 30(4):788-95. PubMed ID: 19150636
[TBL] [Abstract][Full Text] [Related]
8. Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta.
Fortin JP; Gera L; Bouthillier J; Stewart JM; Adam A; Marceau F
J Pharmacol Exp Ther; 2005 Sep; 314(3):1169-76. PubMed ID: 15919764
[TBL] [Abstract][Full Text] [Related]
9. Classification of kinin receptors.
Regoli D; Rizzi A; Perron SI; Gobeil F
Biol Chem; 2001 Jan; 382(1):31-5. PubMed ID: 11258668
[TBL] [Abstract][Full Text] [Related]
10. A fluorescent version of the bradykinin B2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging.
Bawolak MT; Gera L; Bouthillier J; Stewart JM; Adam A; Marceau F
Peptides; 2008 Sep; 29(9):1626-30. PubMed ID: 18565624
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profiles of the human and rabbit B1 receptors.
Gobeil F; Neugebauer W; Nguyen-Le XK; Nea Allogho S; Pheng LH; Blouin D; Whalley ET; Regoli D
Can J Physiol Pharmacol; 1997 Jun; 75(6):591-5. PubMed ID: 9276134
[TBL] [Abstract][Full Text] [Related]
12. [Kinin B1 and B2 receptor antagonists and therapeutic perspectives].
Regoli D; Jukic D; Gobeil F
Therapie; 1995; 50(1):9-18. PubMed ID: 7754483
[TBL] [Abstract][Full Text] [Related]
13. Lack of direct interaction between enalaprilat and the kinin B1 receptors.
Morissette G; Couture JP; Désormeaux A; Adam A; Marceau F
Peptides; 2008 Apr; 29(4):606-12. PubMed ID: 18201802
[TBL] [Abstract][Full Text] [Related]
14. Dual antagonists of the bradykinin B1 and B2 receptors based on a postulated common pharmacophore from existing non-peptide antagonists.
Morissette G; Bouthillier J; Marceau F
Biol Chem; 2006 Feb; 387(2):189-94. PubMed ID: 16497151
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a dual-function peptide that combines aminopeptidase N inhibition and kinin B1 receptor antagonism.
Gera L; Fortin JP; Adam A; Stewart JM; Marceau F
J Pharmacol Exp Ther; 2006 Apr; 317(1):300-8. PubMed ID: 16368899
[TBL] [Abstract][Full Text] [Related]
16. B1 bradykinin receptor homo-oligomers in receptor cell surface expression and signaling: effects of receptor fragments.
Kang DS; Gustafsson C; Mörgelin M; Leeb-Lundberg LM
Mol Pharmacol; 2005 Jan; 67(1):309-18. PubMed ID: 15492119
[TBL] [Abstract][Full Text] [Related]
17. N-Glycosylation of the human kappa opioid receptor enhances its stability but slows its trafficking along the biosynthesis pathway.
Li JG; Chen C; Liu-Chen LY
Biochemistry; 2007 Sep; 46(38):10960-70. PubMed ID: 17711303
[TBL] [Abstract][Full Text] [Related]
18. Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958.
Gera L; Stewart JM; Fortin JP; Morissette G; Marceau F
Int Immunopharmacol; 2008 Feb; 8(2):289-92. PubMed ID: 18182242
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of microglial kinin B1 receptor in diabetic pain neuropathy.
Talbot S; Couture R
Exp Neurol; 2012 Apr; 234(2):373-81. PubMed ID: 22154922
[TBL] [Abstract][Full Text] [Related]
20. Expression of kinin B1 and B2 receptors in immature, monocyte-derived dendritic cells and bradykinin-mediated increase in intracellular Ca2+ and cell migration.
Bertram CM; Baltic S; Misso NL; Bhoola KD; Foster PS; Thompson PJ; Fogel-Petrovic M
J Leukoc Biol; 2007 Jun; 81(6):1445-54. PubMed ID: 17327486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
